Robert E. Goldsby, MD

Robert E. Goldsby, MD

Professor of Clinical Pediatrics, UCSF

Phone: (415) 476-3831 (appts)
0434, UCSF
San Francisco, CA 94143-0434

View on UCSF Profiles

Cancer Center Membership

Program Member » Pediatric Malignancies


University of California, Berkeley, B.A., 1985, Neurobiology
University of Vermont, Burlington, M.D., 1991, Medicine

Professional Experience

  • 7/91-6/94
    Pediatric Internship/Residency, Children's Hospital Oakland, California.
  • 7/94-6/97
    Pediatric Hematology/Oncology Fellowship, University of Utah/Primary Children's Medical Center
  • 7/97-6/99
    Instructor of Pediatrics, University of Utah/Primary Children's Medical Center
  • 7/99-6/02
    Assistant Professor, Department of Pediatrics, University of Utah
  • 7/02-1/15
    Assistant Professor of Clinical Pediatrics, Department of Pediatrics, UCSF
  • 1/15 - present
    Professor of Clinical Pediatrics, UCSF

Honors & Awards

  • 1988
    Summer Research Fellowship Award
  • 1992
    Diplomat, National Board of Medical Examiners (#404330)American Cancer Society
  • 1994
    Certified, American Board of Pediatrics (#237231)
  • 1994-95
    American Cancer Society Clinical Fellowship Award (94-220-1)
  • 1995
    Fellow, American Association of Cancer Research Molecular Biology Workshop
  • 1995-96
    NSRA Institutional Training Grant ( 2 T32 DKO7115-21)
  • 1996-97
    Leukemia Society of America Fellowship Research Grant (5119-97)
  • 1997-02
    Mentored Clinical Scientist Development Award (K08-CA72731)
  • 1999
    Certified, Pediatric Hem/Onc Subspecialty Board
  • 1999
    University of Utah Seed Grant
  • 1999
    Young Investigator, American Association of Cancer Research Clinical Trial Development Workshop
  • 2001-02
    Hope Street Kids Grant
  • 2001-03
    American Cancer Society Grant (RPG-00-299-01-GMC)
  • 2002
    Summer Clinical Research Workshop July 30 September 12
  • 2002-03
    Advanced Training in Clinical Research (ATCR) Certificate Program

Selected Publications

  1. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016 Jan 1; 122(1):116-23.
    View on PubMed
  2. Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2016 Feb; 63(2):370-1.
    View on PubMed
  3. Recurrent stroke in childhood cancer survivors. Neurology. 2015 Sep 22; 85(12):1056-64.
    View on PubMed
  4. Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2015 Sep 10; 33(26):2893-900.
    View on PubMed
  5. Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. Pediatr Blood Cancer. 2015 Nov; 62(11):1947-51.
    View on PubMed
  6. Second malignant neoplasms among children, adolescents and young adults with Wilms tumor. Pediatr Blood Cancer. 2015 Jul; 62(7):1259-64.
    View on PubMed
  7. Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma. Sarcoma. 2014; 2014:902620.
    View on PubMed
  8. Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma. Cancer. 2014 Dec 15; 120(24):3987-93.
    View on PubMed
  9. Pulmonary coccidiomycosis masquerading as refractory metastatic Ewing sarcoma. J Pediatr Hematol Oncol. 2014 Jan; 36(1):e57-60.
    View on PubMed
  10. Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Netw. 2014 Jan; 12(1):21-32; quiz 32.
    View on PubMed
  11. Comparison of Latino and non-Latino patients with Ewing sarcoma. Pediatr Blood Cancer. 2014 Feb; 61(2):233-7.
    View on PubMed
  12. Adverse impact of regional lymph node involvement in osteosarcoma. Eur J Cancer. 2013 Nov; 49(16):3471-6.
    View on PubMed
  13. Radiation, atherosclerotic risk factors, and stroke risk in survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):649-55.
    View on PubMed
  14. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer. 2013 Jul; 49(10):2384-91.
    View on PubMed
  15. Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol. 2013 Feb; 37(1):29-33.
    View on PubMed
  16. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2012 Sep; 10(9):1112-50.
    View on PubMed
  17. Clinical features and outcomes in patients with secondary Ewing sarcoma. Pediatr Blood Cancer. 2013 Apr; 60(4):611-5.
    View on PubMed
  18. Evaluation of plasma annexin V levels in children and young adults with solid tumors. Int J Biol Markers. 2012 Apr-Jun; 27(2):e164-6.
    View on PubMed
  19. CNS demyelination in fibrodysplasia ossificans progressiva. J Neurol. 2012 Dec; 259(12):2644-55.
    View on PubMed
  20. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Horm Metab Res. 2012 Jun; 44(7):539-42.
    View on PubMed

Go to UCSF Profiles, powered by CTSI